

DYOU17.001AUS

**BEST AVAILABLE COPY**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PATENT  
**RECEIVED**  
NOV 12 1999  
TECH CENTER 160

Applicant : Hope, et al.

Appl. No. : 09/201,916

Filed : December 1, 1998

For : VIRAL THERAPEUTICS

Examiner : Unknown



) Group Art Unit 1623

) I hereby certify that this correspondence and all  
) marked attachments are being deposited with  
) the United States Postal Service as first-class  
) mail in an envelope addressed to: Assistant  
) Commissioner for Patents, Washington, D.C.  
) 20231, on

November 4, 1999

DEA 11/4/99

~~October 27, 1999~~

(Date)

Daniel E. Altman  
Daniel E. Altman, Reg. No. 34,115

SUBMISSION OF PRIORITY DOCUMENTS

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Enclosed for filing in the above-identified application is a certified copy of United Kingdom Patent Application No. 9825951.8 filed on November 26, 1998. Priority of invention under 35 United States Code §119 is claimed from this application.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4 Nov. 1999

By: Daniel E. Altman

Daniel E. Altman  
Registration No. 34,115  
Attorney of Record  
620 Newport Center Drive  
Sixteenth Floor  
Newport Beach, CA 92660  
(949) 760-0404

**THIS PAGE BLANK (USPTO)**



The  
Patent  
Office



INVESTOR IN PEOPLE




The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed *Andrew Gensy*  
Dated 15 October 1999


**CERTIFIED COPY OF  
PRIORITY DOCUMENT**

An Executive Agency of the Department of Trade and Industry

**THIS PAGE BLANK (USPTO)**



27NOV98 E407821-10 002246  
P01/7700 0.00 - 9825951.8



# Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

P/5523.GB CTH

2. Patent application number  
(The Patent Office will fill in this part)

**9825951.8**

26 NOV 1998

3. Full name, address and postcode of the or of each applicant  
(underline all surnames)

Medical Research Council  
20 Park Crescent  
London  
W1N 4AL

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

596007001

4. Title of the invention

Viral Therapeutics

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)

21 NEW FETTER LANE  
LONDON  
EC4A 1DA

Patents ADP number (if you have one)

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 59

Claims(s) 3

Abstract 1

Drawing(s) 10

2104

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date



D YOUNG & CO

Agents for the Applicants

26 11 98

12. Name and daytime telephone number of the person to contact in the United Kingdom

Dr C T Harding

01703 634816

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505

b) Write your answers in capital letters using black ink or you may type them

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

## VIRAL THERAPEUTICS

### Field of the invention

5 This invention relates to substances capable of modulating the interaction between viral proteins capable of binding to intracellular lipid globules, cellular adipocyte-specific differentiation-related protein and intracellular lipid globules. The invention also relates to assays for identifying such substances and the use of these substances in affecting viral infection.

10

### Background to the invention

Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis and liver disease. It is estimated that, worldwide, approximately 300 million individuals are infected with the virus, 20% of whom are likely to develop mild to severe liver disease or carcinoma. Apart from the risk of succumbing to the long term effects of infection, these individuals also represent a large reservoir of virus for future transmissions. To date, the only widely used therapy for HCV is treatment with interferon. However, sustained response is achieved in only about 20% of cases. Moreover, no vaccine currently exists to protect against infection. Since growth of the virus has not been possible to date in tissue culture systems, very little is known also about the molecular events which occur during viral replication.

The core protein of HCV is predicted to constitute the capsid of virus particles. From various studies, expression of this protein results in a range of effects on intracellular processes, including a decrease in transcription of genes from HBV and HIV and alterations to apoptosis. There is also evidence from a study on transgenic mice that liver-specific expression of core may be linked to the development of steatosis (fatty liver), a condition commonly found in HCV-infected individuals which is characterised by the accumulation of fat deposits within hepatocytes. Thus, core protein may also influence lipid metabolism within the liver. Other results from studies on human sera suggest that HCV virus particles are found associated with lipoprotein particles which

are produced by the liver. It has also been shown that HCV core protein associates with lipid droplets within cells (Barba *et al.*, 1997; Moradpour *et al.*, 1996). The droplets are storage compartments for both triacylglycerols and cholesterol esters which can be used as substrates for oxidation in mitochondria and for the formation of membranes. In specialised cells, stored cholesterol is used for steroid hormone synthesis.

Within the liver, lipid droplets also function as a site for storage of precursors of the lipid which is secreted from this organ in the form of lipoprotein particles. Although lipid droplets were identified several decades ago and they can be readily detected by staining methods, very little is known about the processes of assembly, storage and disassembly within the cell.

#### Summary of the Invention

We have surprisingly shown that expression of HCV core protein and its resultant association with intracellular lipid droplets results in the loss of a protein, termed adipocyte-specific differentiation-related protein (ADRP), from the droplets. ADRP has been found to associate with lipid droplets in a range of cell types and in certain organs. It has been proposed that ADRP may be required for maintenance of lipid droplets within cells, however the precise function of the protein has not been identified. Furthermore, progressive increases in core expression result in diminishing amounts of ADRP to undetectable levels. We have also identified regions of the HCV core protein which are required for both lipid globule association and down-regulation of ADRP levels. Without wishing to be bound by theory, we believe that displacement of ADRP by HCV core protein may be a factor involved in HCV infection. Thus, the interaction of HCV core with intracellular lipid globules and associated displacement of ADRP represents a target for therapies designed to prevent or reduce the effects and/or progression of HCV infection.

Accordingly the present invention provides a method for identifying a substance for affecting a viral infection, which method comprises:



- (a) providing a lipid globule targeting sequence, as a first component;
- (b) providing a lipid globule, as a second component;
- (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and
- (d) determining whether the substance disrupts the interaction between the first and second components;

wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof.

Disruption by the candidate substance of the interaction between the first and second component is typically indicative that the substance is capable of affecting viral infection.

In a preferred embodiment, the substance to be tested is administered to a cell, the lipid globule targeting sequence is expressed in said cell and the lipid globule is a natural constituent of said cell.

The method of the invention may further comprise:

- (e) administering a virus to a cell in the absence of a said substance which has been determined to disrupt the interaction between the first and second components;
- (f) administering the virus to the cell in the presence of the said substance; and
- (g) determining if the said substance reduces or abolishes the susceptibility of the cell to viral infection or the effects of viral infection.

The present invention also provides a method for identifying a substance capable of affecting a viral infection, which method comprises determining whether said substance can modulate, for example, up-regulate expression of ADRP in a cell. The present invention also provides the use of a substance in the manufacture of a medicament for

use in affecting a viral infection wherein said substance can upregulate expression of ADRP in a mammalian cell.

5 Preferably, in the methods of the invention, the viral infection is a hepatitis infection or other viral infection of the human or animal liver. More preferably the viral infection is an HCV infection.

10 Where cells are used in the methods of the invention, the cells are preferably mammalian cells, more preferably primate cells, for example human cells. Cells which are targeted by the virus of interest are especially preferred for use in the assay methods of the invention. In particular, liver cells are especially preferred.

15 Substances identified by the methods of the invention may be used in methods of affecting viral infection, such as treating or preventing viral infection. Accordingly the present invention provides a substance identified by the method of any one of the preceding claims. Preferably the substance of the invention has not previously been known to affect viral infection.

20 The present invention also provides a process comprising identifying a substance capable of affecting viral infection by the method of the present invention and then either preparing a pharmaceutical composition comprising the substance together with a pharmaceutically acceptable carrier or diluent or modifying the substance to alter its antiviral properties and then, optionally comprising a suitably modified substance substance together with a pharmaceutically acceptable carrier or diluent.

25

The present invention also provides a substance capable of disrupting an interaction between (i) a lipid globule targeting sequence and (ii) a lipid globule for use in affecting a viral infection, wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof.

30

Since we show that HCV core protein and fragments thereof can bind to intracellular

lipid globules, and also affect the interaction between ADRP and intracellular lipid globules, a protein comprising HCV core protein or fragments thereof may be used to reduce or prevent the effect of HCV core protein produced during the course of HCV infection. Accordingly, the present invention provides a protein comprising a lipid  
5 globule targeting sequence for use in preventing or treating a viral infection wherein the targeting sequence comprises an HCV core protein or a fragment, derivative, variant or homologue thereof. Preferably, as with other references to lipid globule targeting sequences above, the targeting sequence comprises amino acids from 125 to 144 and/or 161 to 166 of the HCV core protein as set out in SEQ ID. Nos. 2 and 3, or the  
10 equivalent amino acids in other HCV strains/isolates. More preferably, the lipid globule targeting sequence also comprises a hydrophilic amino acid sequence of at least 8 amino acids

The present invention further provides a polynucleotide encoding a protein comprising a  
15 lipid globule targeting sequence for use in affecting a viral infection.

Thus the present invention relates to substances capable of modulating the interaction of viral proteins, for example HCV core protein, with intracellular lipid globules, in particular where the viral proteins function by reducing the amount of ADRP protein  
20 present in a virally infected cell and associated with intracellular lipid globules/vesicles.

#### Detailed Description of the Invention

Although in general the techniques mentioned herein are well known in the art, reference  
25 may be made in particular to Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (1989) and Ausubel *et al.*, Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

#### **A. Proteins/Polypeptides**

30

The term "protein" includes single-chain polypeptide molecules as well as multiple-

polypeptide complexes where individual constituent polypeptides are linked by covalent or non-covalent means. The term "polypeptide" includes peptides of two or more amino acids in length, typically having more than 5, 10 or 20 amino acids.

#### 5 Lipid globule targeting sequences

The term "lipid globule targeting sequence" means an amino acid sequence which is capable of association with a lipid globule, preferably a biologically occurring lipid globule such as an intracellular lipid globule as found in adipocytes or a secreted lipid globule as found in mammalian milk. In addition, the lipid globule targeting sequence is preferably capable of association with a lipid globule when linked to a protein of interest such that the protein of interest is also associated with the lipid globule by virtue of being linked to the targeting sequence. Lipid globule association may take place within a non-cellular and/or extra-cellular environment, such as in an apparatus - for example a tube or vat. Alternatively, it may take place in a cellular environment where the expressed targeting sequence is directed to intracellular lipid droplets or the membranes of such droplets.

The ability of an amino acid sequence to associate with/target lipid globules can be assessed either *in vitro* or *in vivo*. For example, a candidate targeting sequence may be added to a dispersion of lipid globules (such as a mixture of phospholipid and triacylglycerol) in an aqueous solvent, the mixture sonicated and the degree of partition between aqueous and lipid phases determined by fractionation. Typically fractionation of the mixture would involve increasing the density of the solution with sorbitol or sodium bromide and ultracentrifuging the solution. The lipid complexes migrate to the top of the centrifuge tube and this upper lipid layer is then examined for candidate targeting sequence. Preferably, a suitable lipid globule targeting sequence should partition at least 50:50 lipid:aqueous phase, more preferably at least 75:25, 80:20 or 90:10.

Another suitable test may involve introducing a polynucleotide encoding a candidate sequence, optionally linked to a protein of interest, into a milk-producing cell in culture and determining whether, the targeting sequence/protein of interest has been secreted into

the culture medium. The immunocytochemical technique illustrated in the Examples may also be used.

- 5 Lipid globule targeting sequences used according to the present invention are also preferably capable of displacing ADRP from intracellular lipid globules and/or of reducing the levels of ADRP protein in a cell when expressed in, or administered to, the cell (as illustrated for HCV core protein in the Examples). Suitable techniques for determining whether a candidate sequence has these properties are described below.
- 10 Suitable lipid globule targeting sequences may be obtained from an HCV core protein. The amino acid sequence of the HCV core protein has been obtained for a large number of different HCV isolates. These sequences are readily available to the skilled person. One such sequence, for HCV strain Glasgow, is set out in SEQ ID No. 1. The means for cloning and identifying new HCV strains, and thus obtaining further core sequences, are
- 15 described in EP-B-318,216.

- According to the present invention, it is preferred to use fragments of the HCV core protein which are capable of targeting molecules, to which they are linked, to lipid globules. Amino acid numbering for preferred fragments set out below is with reference
- 20 to SEQ ID. No. 1. However it will be understood that equivalent fragments of the core protein of other HCV strains/isolates may also be used. An HCV core protein-derivable lipid globule targeting sequence of the invention is preferably a minimal amino acid sequence which can target a molecule, typically a protein, to lipid globules. The minimal sequence will typically comprise a hydrophobic amino acid sequence derived from amino
- 25 acids 120 to 169 of an HCV core sequence, preferably linked to a hydrophilic amino acid sequence of at least 8, preferably 10, more preferably at least 12 amino acids. It is not necessary for the hydrophilic sequence to be contiguous with the hydrophobic sequence. For example, a protein of interest may be placed between the two sequences such that the hydrophilic sequence is at the N-terminus and the hydrophobic sequence is
- 30 at the C-terminus.

The hydrophobic amino acid sequence typically comprises at least 10, preferably at least 15 or 20 contiguous amino acids and has a hydropathy index of at least +40 kJ/mol (determined, for example, theoretically as described by Engelman *et al.*, 1986. The hydrophilic amino acid sequence typically has a hydropathy plot of less than -20 kJ/mol, preferably less than -40 kJ/mol.

Preferred HCV core fragments contain amino acids 161 to 166 (SEQ ID. No. 3). It is also preferred to use fragments of the HCV core protein that contain amino acids 125 to 144 (SEQ ID. No. 2). In a preferred embodiment, HCV core protein fragments of the invention contain both amino acids 125 to 144 and amino acids 161 to 166. In an especially preferred embodiment, the lipid targeting sequence of the invention comprises a hydrophilic amino acid sequence containing amino acids 1 to 8 of the HCV core sequence. Other preferred fragments contain amino acids 1 to 173 or 1 to 169.

Since it has also now been shown that amino acids 9 to 43, 49 to 75, 80 to 118 and 155 to 161 are not required for lipid association, preferred HCV core protein fragments of the invention lack one or more of these sequences. Suitable fragments will be at least about 5, e.g. 10, 12, 15 or 20 amino acids in size and preferably have less than 100, 90, 80, 70, 60 or 50 amino acids. In a preferred aspect, fragments contain an HCV epitope.

Lipid globule targeting sequences of the invention, for example HCV core protein sequences and fragments thereof, may, however, be part of a larger polypeptide, for example a fusion protein. In this case, the additional polypeptide sequences are preferably polypeptide sequences with which the lipid globule targeting sequence of the invention is not normally associated.

It will be understood that lipid globule targeting sequences of the invention are not limited to sequences obtained from HCV core protein but also include homologous sequences obtained from any source, for example related viral proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof. Thus, the present invention covers variants, homologues or derivatives of the targeting sequences of

the present invention, as well as variants, homologues or derivatives of the nucleotide sequence coding for the targeting sequences of the present invention.

5 In the context of the present invention, a homologous sequence is taken to include an amino acid sequence which is at least 60, 70, 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 5, preferably 8, 10, 15, 20, 30 or 40 amino acids with an HCV core protein lipid targeting sequence, for example as shown in the sequence listing herein. In particular, homology should typically be considered with respect to those regions of the targeting sequence known to be essential  
10 for lipid globule association rather than non-essential neighbouring sequences. Homology comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

15 Sequence homology (or identity) may moreover be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST algorithm is described in detail at [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html), which is  
20 incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least about 7, preferably at least about 9 and  
25 most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe  
30 significance to their findings using the statistical methods of Karlin and Altschul (see [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html)) with a few enhancements. The

BLAST programs were tailored for sequence similarity searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul *et al.*, 1994.

5

The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

10

**blastp** - compares an amino acid query sequence against a protein sequence database;

**blastn** - compares a nucleotide query sequence against a nucleotide sequence database;

**blastx** - compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

15

**tblastn** - compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

20

**tblastx** - compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

25

**HISTOGRAM** - Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

**DESCRIPTIONS** - Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also EXPECT and CUTOFF.

30



ALIGNMENTS - Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see EXPECT and CUTOFF below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

EXPECT - The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the EXPECT threshold, the match will not be reported. Lower EXPECT thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

CUTOFF - Cutoff score for reporting high-scoring segment pairs (HSPs). The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value. Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

MATRIX - Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.

STRAND - Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

5 FILTER - Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993), or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993), or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g. hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching  
10 against database sequences.

Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in protein sequences (e.g., "XXXXXXXXXX").

15

Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

20 It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

25 NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

30

Other computer program methods to determine identify and similarity between the two sequences include but are not limited to the GCG program package (Devereux *et al* 1984) and FASTA (Atschul *et al.* 1990).

- 5 Lipid globule targeting sequences of the invention, for example HCV core protein sequences, variants, homologues and fragments thereof, may be modified for use in the present invention. Typically, modifications are made that maintain the hydrophobicity/hydrophilicity of the sequence Amino acid substitutions may be made, for example from 1, 2 or 3 to 10, 20 or 30 substitutions provided that the modified  
10 sequence retains the ability to target molecules to lipid globules. Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.

Conservative substitutions may be made, for example according to the Table below.

- 15 Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

ALIPHATIC	Non-polar	G A P
		I L V
	Polar - uncharged	C S T M
		N Q
	Polar - charged	D E
		K R
AROMATIC		H F W Y

- 20 The terms "variant", "homologue" or "derivative" in relation to the targeting sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing

the resultant amino acid sequence has a lipid globule targeting activity, preferably having at least the same activity of the targeting sequences presented in the sequence listings.

Proteins of the invention comprising lipid globule targeting sequences are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Proteins of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional activation domains) and  $\beta$ -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the HCV core protein sequence and/or between the HCV core protein sequence and the protein of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the lipid targeting effect of the lipid globule targeting sequence. The targeting sequence may be linked to either the N-terminus or the C-terminus of the fusion protein partners or proteins of interest

Proteins of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated. A protein of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the protein in the preparation is a protein of the invention.

## 2. Adipocyte-specific differentiation related protein

In another embodiment of the *in vitro* assay methods of the present invention, ADRP may be added to the mixture to compete with a lipid globule targeting sequence. ADRP protein (also known as adipophilin) can be obtained in a number of ways, for example by purification from mammalian milk or mammalian cell lines (Heid *et al.*, 1998). Alternatively, ADRP can be obtained by recombinant means, as described above for

lipid globule targeting sequences. The nucleotide sequence of human ADRP, for example, is given in US Patent No. 5,739,009 and shown in SEQ ID. No. 4. Since ADRP is capable of binding lipid globules, it can also be considered to be a lipid globule targeting sequence within the scope of the invention. Consequently, the disclosure  
5 above and below relating to lipid globule targeting sequences also generally applies, where appropriate, to ADRP sequences, for example the use of fragments, homologues, derivatives and variants. In particular, ADRP sequences may be modified for use in the assays of the present invention as described above.

10 **B. Polynucleotides and vectors.**

Polynucleotides of the invention comprise nucleic acid sequences encoding the the lipid globule targeting sequences of the invention. It will be understood by a skilled person that numerous different polynucleotides can encode the same polypeptide as a result of  
15 the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may, using routine techniques, make nucleotide substitutions that do not affect the polypeptide sequence encoded by the polynucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.

20

Polynucleotides of the invention may comprise DNA or RNA. They may be single-stranded or double-stranded. They may also be polynucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and  
25 phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the *in vivo* activity or life span of polynucleotides of the invention.

30

The terms "variant", "homologue" or "derivative" in relation to the nucleotide sequence coding for the lipid targeting sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence providing the resultant nucleotide sequence codes for a protein having lipid targeting activity, preferably having at least the same activity of the targeting sequences presented in the sequence listings.

As indicated above, with respect to sequence homology, preferably there is at least 75%, more preferably at least 85%, more preferably at least 90% homology to the sequences shown in the sequence listing herein. More preferably there is at least 95%, more preferably at least 98%, homology. Nucleotide homology comparisons may be conducted as described above.

The present invention also encompasses nucleotide sequences that are capable of hybridising selectively to the sequences presented herein, or any variant, fragment or derivative thereof, or to the complement of any of the above. Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.

The term "hybridization" as used herein shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" (Coombs J (1994) Dictionary of Biotechnology, Stockton Press, New York NY) as well as the process of amplification as carried out in polymerase chain reaction technologies as described in Dieffenbach CW and GS Dveksler (1995, PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview NY).

Polynucleotides of the invention capable of selectively hybridising to the nucleotide sequences presented herein, or to their complement, will be generally at least 70%, preferably at least 80 or 90% and more preferably at least 95% or 98% homologous to the corresponding nucleotide sequences presented herein over a region of at least 20, preferably at least 25 or 30, for instance at least 40, 60 or 100 or more contiguous

nucleotides. Preferred polynucleotides of the invention will comprise regions homologous to nucleotides 715 to 774 and/or nucleotides 826 to 840 of SEQ ID No. 1, preferably at least 80 or 90% and more preferably at least 95% homologous to nucleotides 715 to 774 and/or nucleotides 826 to 840 of SEQ ID No. 1.

5

The term "selectively hybridizable" means that the polynucleotide used as a probe is used under conditions where a target polynucleotide of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening. In this event, background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA. The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with  $^{32}\text{P}$ .

10

15

Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques, Methods in Enzymology, Vol 152, Academic Press, San Diego CA), and confer a defined "stringency" as explained below.

20

Maximum stringency typically occurs at about  $T_m - 5^\circ\text{C}$  ( $5^\circ\text{C}$  below the  $T_m$  of the probe); high stringency at about  $5^\circ\text{C}$  to  $10^\circ\text{C}$  below  $T_m$ ; intermediate stringency at about  $10^\circ\text{C}$  to  $20^\circ\text{C}$  below  $T_m$ ; and low stringency at about  $20^\circ\text{C}$  to  $25^\circ\text{C}$  below  $T_m$ . As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.

25

In a preferred aspect, the present invention covers nucleotide sequences that can hybridise to the nucleotide sequence of the present invention under stringent conditions (e.g.  $65^\circ\text{C}$  and  $0.1\times\text{SSC}$  { $1\times\text{SSC} = 0.15\text{ M NaCl}, 0.015\text{ M Na}_3\text{ citrate pH } 7.0$ }).

30

Where the polynucleotide of the invention is double-stranded, both strands of the duplex, either individually or in combination, are encompassed by the present invention. Where the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention.

5

Polynucleotides which are not 100% homologous to the sequences of the present invention but fall within the scope of the invention can be obtained in a number of ways. Other HCV core protein variants of the HCV core protein sequence described herein may be obtained for example by probing DNA libraries made from a range of HCV infected individuals, for example individuals from different populations. In addition, other viral, or cellular homologues particularly cellular homologues found in mammalian cells (e.g. rat, mouse, bovine and primate cells), may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein. Such sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other animal species, and probing such libraries with probes comprising all or part of SEQ ID. 1 under conditions of medium to high stringency. Similar considerations apply to obtaining species homologues and allelic variants of ADRP.

15

20 Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the lipid globule targeting sequences of the present invention. Conserved sequences can be predicted, for example, by aligning the HCV core protein amino acid sequences from several HCV isolates. Such HCV sequence comparisons are widely available in the art. The primers will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.

25

Alternatively, such polynucleotides may be obtained by site directed mutagenesis of characterised lipid globule targeting sequences, such as SEQ ID. No 1. This may be useful where for example silent codon changes are required to sequences to optimise codon

30



preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.

5

Polynucleotides of the invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors. Such primers, probes and other fragments will be at least 15,  
10 preferably at least 20, for example at least 25, 30 or 40 nucleotides in length, and are also encompassed by the term polynucleotides of the invention as used herein.

Polynucleotides such as a DNA polynucleotides and probes according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the  
15 art. They may also be cloned by standard techniques.

In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.  
20

Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques. This will involve making a pair of primers (e.g. of about 15 to 30 nucleotides) flanking a region of the lipid targeting sequence which it is desired to clone, bringing the primers into contact with mRNA or  
25 cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e.g. by purifying the reaction mixture on an agarose gel) and recovering the amplified DNA. The primers may be designed to contain suitable restriction enzyme recognition sites so that the amplified DNA can be cloned into a  
30 suitable cloning vector

Polynucleotides of the invention can be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Thus in a further embodiment, the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector. The vector may be recovered from the host cell. Suitable host cells include bacteria such as *E. coli*, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells.

Preferably, a polynucleotide of the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.

A particularly preferred vector for use in the present invention comprises the control sequences naturally associated with ADRP genes, such as the human ADRP gene. Typically, the control sequences are operably linked to a reporter gene. Such a vector may be used in the assays described below for identifying modulators of ADRP expression. The control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

Vectors of the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Alternatively, vectors comprising the control sequences naturally associated with ADRP genes

operably linked to a reporter gene as a reporter construct may be transformed or transfected into a host cell, for example for use in assays of the invention which measure the effect of candidate substances on transcription from the reporter construct in a cellular environment.

5

The vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.

Control sequences operably linked to sequences encoding the protein of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in. The term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

20 The promoter is typically selected from promoters which are functional in mammalian, cells, although prokaryotic promoters and promoters functional in other eukaryotic cells may be used. The promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. With respect to eukaryotic promoters, they may be promoters that function in a ubiquitous manner (such as promoters of  $\alpha$ -actin,  $\beta$ -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). Tissue-specific promoters specific for liver cells are particularly preferred, for example hepatitis B viral promoters, apolipoprotein AII promoters human serum amyloid P component promoters or human protein C gene promoters. They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney

murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter. As discussed above ADRP promoters are particularly preferred for use in reporter constructs.

5

It may also be advantageous for the promoters to be inducible so that the levels of expression of the heterologous gene can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.

10

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

15

### **C. Host cells**

Vectors and polynucleotides of the invention (and reporter gene constructs described below) may be introduced into host cells for the purpose of replicating the  
20 vectors/polynucleotides and/or expressing the proteins of the invention encoded by the polynucleotides of the invention. Although the proteins of the invention may be produced using prokaryotic cells as host cells, it is preferred to use eukaryotic cells, for example yeast, insect or mammalian cells, in particular mammalian cells. Particularly preferred cells are those with substantial amounts of intracellular lipid droplets/globules,  
25 for example adipocytes. Cells which are targeted by a particular virus which it is desired to treat, for example liver cells, are also preferred.

Vectors/polynucleotides of the invention may introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation and  
30 electroporation. Where vectors/polynucleotides of the invention are to be administered to animals, several techniques are known in the art, for example infection with

recombinant viral vectors such as herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation.

#### **D. Protein Expression and Purification**

5

Host cells comprising polynucleotides of the invention may be used to express proteins of the invention. Host cells may be cultured under suitable conditions which allow expression of the proteins of the invention. Expression of the proteins of the invention may be constitutive such that they are continually produced, or inducible, requiring a stimulus to initiate expression. In the case of inducible expression, protein production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG.

Proteins of the invention can be extracted from host cells by a variety of techniques known in the art, including enzymatic, chemical and/or osmotic lysis and physical disruption. Although a large number of different purification protocols may be used, given the ability of the HCV core proteins of the invention to target proteins of interest to lipid globules, a preferred extraction/purification protocol involves centrifuging cell homogenates at high speed (for example 100,000 g for 60 mins at 2 to 4°C) and removing the resulting layer of floating lipids. This will function as a primary purification step. Further purification can then be performed if necessary using, for example, column chromatography such as ion-exchange or affinity chromatography. Cells which secrete lipid globules may also conveniently be used and the lipid globules harvested from the culture supernatant.

25

Proteins associated with the membrane surrounding fat globules can be fractionated into soluble and insoluble fractions by extraction with 1% (w/v) Triton X-100/1.5 M NaCl/10 mM Tris (pH 7.0), by extraction with 1.5% (w/v) dodecyl  $\beta$ -D maltoside/0.75 M aminohexanoic acid/10 mM Hepes (pH 7.0) or by sequential extraction with these two detergent-containing solutions (Patton and Huston, 1986). Suspension of the fat globule components in the detergent-containing solution can be achieved by using an

30

all-glass homogenizer, and keeping on ice for 30 to 60 min, after which insoluble and soluble materials can be separated by centrifugation for 60 min at 2°C and 150,000 g. The above conditions can be modified to analyse whether core protein or a fusion protein containing core as a component is attached to fat globules. Other detergents, both ionic and non-ionic, along with salt solutions at various concentrations could be used to derive the proteinaceous material from fat globules. The incubation times and temperatures may be optimised by empirical means.

## E. Assays

### 1. Assays for substances that disrupt the interaction between a lipid globule targeting sequence and a lipid globule

#### i. Candidate substances

A substance which disrupts an interaction between the lipid globule targeting sequence and lipid globule may do so in several ways. It may directly disrupt the binding of the lipid globule targeting sequence to the lipid globule by, for example, binding to the lipid globule targeting sequence and masking or altering the site of interaction with the lipid globule. Alternatively, the candidate substance may compete for binding sites on the lipid globule surface and displace the lipid globule targeting sequence. Candidate substances of these types may conveniently be screened by *in vitro* binding assays as, for example, described below. Candidate substances may also be screened using an “*in vivo*” whole cell assay as described below. The term ‘*in vivo*’ is intended to encompass experiments with cells in culture as well as experiments with intact multicellular organisms.

A substance which can bind directly to the lipid globule targeting sequence may also inhibit an interaction between the lipid globule targeting sequence and the lipid globule by altering the subcellular localisation of the lipid globule targeting sequence thus

preventing the two components from coming into contact within the cell. This can also be tested *in vivo* using, for example the *in vivo* assays described below.

5 Alternatively, instead of preventing the association of the components directly, the substance may suppress or enhance the biologically available amount of lipid globule targeting sequence (for example a viral protein component). This may be by inhibiting expression of the viral protein comprising the lipid globule targeting sequence, for example at the level of transcription, transcript stability, translation, post-translational processing or post-translational stability. An example of such a substance would be  
10 antisense RNA which suppresses the amount of HCV core protein mRNA translated into protein.

Suitable candidate substances include viral peptides, which in some cases may especially be of from about 5 to 20 amino acids in size, based on, for example, lipid globule  
15 targeting motifs found within the HCV core protein, or variants of such peptides in which one or more residues have been substituted. Peptide fragments of ADRP may also be used, including modified variants thereof. Peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides may be used.

20

Suitable candidate substances also include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies) which are specific for the lipid globule targeting sequence or surface constituents of the lipid globules. Furthermore, combinatorial libraries, peptide and  
25 peptide mimetics, defined chemical entities such as organic and inorganic compounds, oligonucleotides, and natural product libraries may be screened for activity as inhibitors of an interaction between the lipid globule targeting sequence and a lipid globule in assays such as those described below. The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances  
30 of those batches which show inhibition tested individually. Candidate substances which show activity in *in vitro* screens such as those described below can then be tested in *in*

*vivo* systems, such as mammalian cells which will be exposed to the inhibitor and tested, for example, for susceptibility to viral infection.

ii. Assays

5

The assays of the invention may be *in vitro* assays or *in vivo* assays, for example using cell lines or an animal model, such as mice or chimpanzees.

*In vitro* assay systems

10

One type of *in vitro* assay for identifying substances which disrupt an interaction between the lipid globule targeting sequence and a lipid globule involves measuring in the presence or absence of a candidate substance the association of a targeting sequence with lipid globules formed *in vitro*. Binding of targeting sequences to lipid globules may be assessed by adding a targeting sequence to a dispersion of lipid globules (such as a mixture of phospholipid and triacylglycerol) in an aqueous solvent, sonicating the mixture and determining by fractionation the degree of partition between aqueous and lipid phases. Typically fractionation of the mixture would involve increasing the density of the solution with sorbitol or sodium bromide and ultracentrifuging the solution. The lipid complexes migrate to the top of the centrifuge tube and this upper lipid layer is then examined for targeting sequence. This is performed in the presence or absence of the candidate substance whose inhibitory activity it is desired to test. Typically, a candidate substance is deemed to inhibit the lipid globule targeting sequence if it causes a reduction of at least 50%, preferably at least 60, 70, 80 or 90% in the amount of targeting sequence associated with the lipid phase in the absence of the candidate substance.

25

The candidate substance may be pre-incubated with the lipid globule targeting sequence or with a lipid globule or added to the reaction mixture after pre-incubation of the lipid globule targeting sequence with a lipid globule.

30



Another type of *in vitro* assay for identifying substances which disrupt an interaction between the lipid globule targeting sequence and a lipid globule or a lipophilic surface involves the following:

- 5 Proteins incorporating the lipid globule targeting sequence, for example a fragment of HCV core protein, and optionally ADRP, may be translated *in vitro* from RNA transcripts encoding these polypeptides. Reactions would be supplemented with membranes originating from tissue culture cells (e.g. microsomal membranes) or a lipophilic surface which had been artificially created (e.g. a liposome) to which the *in vitro* translated proteins can bind. Binding may be assessed by purification of the lipid components of reactions (e.g. by centrifugation). Alternatively a chip format (for example BIAcore<sup>TM</sup> - Biacore AB) wherein the chip has a lipid surface may be used to assess binding.
- 10
- 15 The ability of candidate substances to disrupt association of the targeting sequence and/or ADRP with lipid can be examined by adding to reactions candidate substances during synthesis of the proteins. Thus, the effects of substances on core/lipid globule targeting sequences and ADRP association with lipid can be compared. Preferably, a suitable inhibitor of a lipid globule targeting sequence is capable of inhibiting binding of
- 20 viral lipid targeting sequences such as HCV core to lipid globules without affecting binding of ADRP.

#### *In vivo* assay systems

- 25 *In vivo* assays for identifying compounds that disrupt an interaction between the lipid globule targeting sequence and a lipid globule typically involve administering a candidate substance to a cell which expresses a lipid globule targeting sequence, for example a fragment of HCV core protein, and determining if the ability of the targeting sequence to associate with intracellular lipid globules has been affected, for example
- 30 reduced or abolished. Thus the association of the targeting sequence with intracellular

lipid globules is determined in the absence of the candidate substance and in the presence of the candidate substance and the results compared.

5 Association of the lipid globule targeting sequence with intracellular globules is typically determined by immunofluorescence microscopy using an antibody which recognises the targeting sequence and an antibody or stain which recognises intracellular lipid globules or a surface component of the globules. If the targeting sequences is able to bind to the lipid globules, then the targeting sequence will substantially co-localise with the lipid globules. A suitable procedure is described in the Examples. In addition, since we  
10 show that HCV core protein can displace ADRP from lipid globules, the co-localisation of endogenous ADRP with lipid globules may also be determined in the presence and absence of the candidate substance.

A candidate substance is generally considered to be capable of disrupting the interaction  
15 between the lipid globule targeting sequence and intracellular lipid globules if, as determined by immunofluorescence microscopy, less than 50% of the detectable targeting sequence protein co-localises with intracellular lipid globules, preferably less than 60%, more preferably less than 70, 80 or 90%. Preferably, a suitable inhibitor of a lipid globule targeting sequence is capable of disrupting the interaction of viral lipid  
20 targeting sequences such as HCV core with intracellular lipid globules/surface components without affecting the interaction of ADRP with intracellular lipid globules/surface components.

It will be appreciated by the skilled person that other techniques are available for  
25 determining localisation of proteins and lipid within intact cells and that these techniques are also applicable to the assays of the present invention.

The candidate substance, i.e. the test compound, may be administered to the cell in one or more ways. For example, it may be added directly to the cell culture medium or  
30 injected into the cell. Alternatively, in the case of polypeptide candidate substances, the cell may be transfected with a nucleic acid construct which directs expression of the

polypeptide in the cell. Preferably, the expression of the polypeptide is under the control of a regulatable promoter, for example so that expression is induced shortly before it is desired to administer the candidate substance.

- 5 Another suitable test may involve introducing a polynucleotide encoding a targeting sequence of the invention, optionally linked to a protein of interest, into a milk-producing cell in culture and determining whether, the targeting sequence/protein of interest has been secreted into the culture medium. This would be carried out in the presence or absence of the candidate substance.

10

2. Assays for substances that are capable of modulating ADRP expression in cells

i. Candidate substances

- 15 Substances that modulate ADRP expression, preferably up-regulate ADRP expression so that the levels of ADRP protein in a cell are increased, may do so by one or more of several mechanisms. For example, a substance may increase levels of transcription from endogenous ADRP genes, stabilise ADRP mRNA levels and/or stabilise ADRP protein. Transcription may be increased from endogenous ADRP genes by, for example, the use  
20 of a transcriptional activator that activates transcription from endogenous ADRP genes or a substance that modifies the effect of a transcriptional inhibitor of endogenous ADRP genes. Thus tests for modulation of ADRP expression include determining the effect of a candidate substance on ADRP mRNA levels and/or ADRP protein levels.

- 25 The term "modulate" in the context of the ADRP expression means a change or alteration in the levels of ADRP mRNA and/or ADRP protein.

Suitable candidate substances include substances known to modulate cellular transcription and/or lipid metabolism. Examples of substances which may affect ADRP  
30 expression include non-steroidal anti-inflammatory drugs such as ibuprofen and indomethacin, and drugs known to affect lipid metabolism such as fibrates and

thiazolidinediones. Furthermore, combinatorial libraries, peptide and peptide mimetics, in particular peptides from panels of peptides comprising random sequences or sequences which have been varied consistently to provide a maximally diverse panel of peptides, defined chemical entities such as organic and inorganic compounds, oligonucleotides, and natural product libraries may be screened for activity as modulators of ADRP expression in assays such as those described below. The candidate substances may be used in an initial screen in batches of, for example 10 substances per reaction, and the substances of those batches which show inhibition tested individually. In addition, candidate substances which show activity in *in vitro* screens such as those described below can then be tested in *in vivo* systems, such as mammalian cells which will be exposed to the inhibitor and tested, for example, for susceptibility to viral infection.

ii. Assays

The assays of the invention may be *in vitro* assays or *in vivo* assays, for example using cell lines or an animal model.

*In vitro* assay systems

An *in vitro* assay system of the invention typically measures the effect on transcription from a polynucleotide construct comprising an ADRP promoter linked to a polynucleotide whose transcribed, and optionally translated, product is capable of detection, for example the naturally occurring ADRP coding sequence or a reporter gene such as luciferase. Techniques for detecting and quantitating transcription products are well known in the art and include, for example hybridisation to labelled probes and direct quantitation of transcribed products by the use of labelled nucleotides which are incorporated during transcription. Translated products may also be detected using well known techniques such as SDS-PAGE and Western blotting, or in the case of biologically active products, suitable assays for detecting said activity (such as CAT assays or chemiluminescence assays).

A suitable *in vitro* assay may for example, be conducted using extracts of mammalian cells, typically supplemented with buffers and nucleotide mixes. Reporter constructs comprising polynucleotides containing ADRP promoter constructs linked to a reporter gene may be added to the mix, or endogenous genomic DNA used.

The effect of a candidate substance on ADRP expression may be determined by measuring levels of transcription from the ADRP promoter construct (endogenous or otherwise) in the presence and absence of the candidate substance and comparing the results. Preferably, a control promoter construct should also be tested to ensure that any effect on ADRP expression is specific to the ADRP promoter and is not simply the result of general transcriptional inhibition. A candidate substance is typically considered to modulate ADRP expression if the levels of transcriptional are altered by at least 30%, preferably at least 50, 60, 70, 80 or 90%. Any affect on the control promoter should preferably be accounted for when calculating changes in ADRP transcription.

#### *In vivo* assay systems

Modulation of ADRP expression can also conveniently be measured *in vivo*, typically using mammalian cell lines. As with *in vitro* systems, both reporter constructs and endogenous ADRP genes may be used. In a preferred embodiment, the assay uses mammalian cells stably transfected with a polynucleotide comprising a reporter construct which contains an ADRP promoter operably linked to a reporter gene, for example chloramphenicol transferase (CAT) or luciferase. The cell also preferably comprises a stably transfected control promoter sequence operably linked to a second reporter gene which can be distinguished from the first reporter gene. Typically, levels of transcription from the ADRP construct and the control construct are measured in the absence of a candidate substance and then measured in the presence of a candidate substance. The effect of the candidate substance on transcription from the ADRP reporter construct (or endogenous ADRP gene) can then be determined, taking into

account any general effect on transcription as indicated by the result obtained for the control reporter construct.

5 In another embodiment, ADRP expression is measured by determining the amount of ADRP protein in cells before administration of the candidate substance and after administration of the candidate substance. As described above, protein levels are typically measured by analysing cell extracts by SDS-PAGE and detecting the ADRP protein using Western blotting. Alternatively, the cells used in the assay of the invention may comprise a reporter construct containing an ADRP promoter operably  
10 linked to a nucleotide sequence encoding a detectable polypeptide product, such as CAT. In a particularly preferred embodiment, the detectable product encodes an enzyme which can cleave a cellular or exogenously added substance causing a detectable change in the absorption spectrum or emission spectrum of the cell or cell medium at a particular wavelength. This will facilitate the large-scale screening of candidate substances in, for  
15 example a microtitre plate assay format.

Administration of candidate substances to mammalian cell lines and generation of host mammalian cell lines comprising reporter constructs can be carried out as described above.

20

### 3. Testing candidate substances for anti-viral activity

Candidate substances that are identified by the method of the invention as disrupting an interaction between a lipid globule targeting sequence and a lipid globule, or modulating  
25 ADRP expression may be tested for their ability to, for example, reduce susceptibility of cells to viral infection. Such compounds could be used therapeutically to affect viral infection, for example to prevent or treat viral infection.

Typically, an assay to determine the effect of a candidate substance identified by a  
30 method of the invention on the susceptibility of cells to viral infection comprises:

- (a) administering a virus, for example HCV, to a cell, in the absence of the candidate substance;
- (b) administering the virus to the cell in the presence of the candidate substance; and
- 5 (c) determining if the candidate substance reduces or abolishes the susceptibility of the cell to viral infection.

The candidate substance may be administered before, or concomitant with, the virus to establish if infection is prevented. Alternatively, the candidate substance may be  
10 administered subsequent to viral infection to establish if viral infection can be treated using the candidate substance. Administration of candidate substances to cells may be performed as described above.

The assay is typically carried out using mammalian cell lines, but an animal model could  
15 be employed instead, such as chimpanzees in the case of HCV. The virus is contacted with cells, typically cells in culture. The cells may be cells of a mammalian cell line, in particular mammalian cells susceptible to infection by the virus in the absence of the candidate substance, for example in the case of HCV, liver cells.

20 Techniques for assaying infectivity of viruses are well-known in the art. As well as using plaque assays, levels of viral infection can be determined by using recombinant viruses which comprise a reporter gene, for example *lacZ*. The use of a histochemically detectable reporter gene is especially preferred when experiments are performed with animals. In the case of HCV, plaque assays cannot be used. A suitable method for  
25 determining the level of HCV production in an infected animal is to perform RT-PCR analysis of the amount of positive-strand nucleic acid material in cells or serum. In addition, the presence of negative-strand RNA in cells, as determined by RT-PCR, is taken to mean that there is active viral replication.

30 In a preferred embodiment of the above-described assays, lipid globule targeting sequence and derivatives thereof are used in an experimental system to study normal

cellular interactions. For example, derivatives of viral proteins such as HCV core protein or derivatives of ADRP, including deletion, insertion and substitution mutants, can be used to disrupt an interaction between ADRP and lipid globules. This can be tested *in vitro* or *in vivo* using the assays described above. The interaction between  
5 ADRP and lipid globules can also be disrupted *in vivo* by introducing a lipid globule targeting sequence or derivatives thereof, including deletion, insertion and substitution mutants, into cells *in vivo*, preferably mammalian cells, more preferably human cells.

Lipid globule targeting sequences and their derivatives can be introduced into the cells  
10 using techniques described above, for example transfection of nucleic acid constructs encoding lipid globule targeting sequences, or using viral vectors. The effect of this disruption can be determined as described above. Any *in vitro* data obtained may be used to assist in the rational design of lipid globule targeting sequences for use in the *in vivo* studies. In addition, the precise regions/amino acid residues of lipid globule  
15 targeting sequences which bind to lipid globules can be determined by *in vitro* binding studies using lipid globule targeting sequence derivatives. This will also assist in the rational design of lipid globule targeting sequence derivatives for use in the *in vivo* studies.

20 Thus viral lipid globule targeting sequences, which are readily distinguished from cellular constituents, may be used as a tool to investigate intracellular lipid metabolism.

#### **F. Therapeutic Uses**

25 Substances capable of disrupting an interaction between a viral lipid globule targeting sequence and an intracellular globule may be used to affect a viral infection in a human or animal, in particular to treat or prevent a viral infection. Such substances may have been identified by the assay methods of the invention or otherwise.

30 Substances that are capable of modulating ADRP expression may also be used to affect a viral infection in a human or animal, in particular to treat or prevent a viral infection.



Such substances may have been identified by the assay methods of the invention or otherwise. For example, the non-steroidal anti-inflammatory drugs ibuprofen and indomethacin have been shown to stimulate ADRP expression. Consequently, the present invention provides the use of ibuprofen and/or indomethacin in the manufacture  
5 of a medicament for use in affecting a viral infection, preferably an HCV infection.

### G. Compositions/Administration

Proteins of the invention and substances identified or identifiable by the assay methods  
10 of the invention may preferably be combined with various components to produce compositions of the invention. Preferably the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use). Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition of the  
15 invention may be administered by direct injection. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Typically, each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.

20 Polynucleotides/vectors encoding polypeptide components for use in affecting viral infections may be administered directly as a naked nucleic acid construct, preferably further comprising flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic  
25 acid administered may typically be in the range of from 1  $\mu$ g to 10 mg, preferably from 100  $\mu$ g to 1 mg.

Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents.  
30 Example of these agents include cationic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectam<sup>TM</sup> and transfectam<sup>TM</sup>).

Typically, nucleic acid constructs are mixed with the transfection agent to produce a composition.

5 Preferably the polynucleotide or vector of the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline. The composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

10 The routes of administration and dosages described are intended only as a guide since a skilled practitioner will be able to determine readily the optimum route of administration and dosage for any particular patient and condition.

The invention will be described with reference to the following Examples which are  
15 intended to be illustrative only and not limiting. The Examples refer to the following Figures.

#### Brief Description of the Figures

20 Figure 1 shows Western blots probed with antibodies to HCV core protein  
Figure 2 shows confocal microscopy images of the intracellular localisation of core proteins and lipid droplets.  
Figure 3 shows confocal microscopy images of cells illustrating the effect of expression of HCV core proteins on the ability to detect ADRP in BHKC13 cells.  
25 Figure 4 shows confocal microscopy images of cells illustrating the effect of expression of HCV core protein on the abundance of ADRP.  
Figure 5 shows Western blots probed with antibodies to HCV core protein and adipophilin  
Figure 6 shows Western blots probed with antibodies to HCV core protein.

### Detailed Description of the Figures

#### **Figure 1**

##### **Analysis of the core proteins made by the pSFV and pgHCV constructs.**

- 5 A. Western blot analysis of extracts prepared from cells which were harvested 20 hours after electroporation. Aliquots of extracts containing the same number of cell equivalents were analysed with antibody JM122. The samples were from cells electroporated with RNA from the following constructs: lane 1, pSFV.1-195; lane 2, pSFV.1-173; lane 3, pSFV.1-169; lane 4, pSFV.1-153; lane 5, pSFV.Δ155-161; lane 6, pSFV. Δ161-166; lane 7, no RNA.

Arrows denote the forms of core which have (labelled C) and have not (labelled UC) been cleaved at the internal processing site.

- 15 B. *In vitro* translation of core proteins. Products of reactions were electrophoresed on a 10% polyacrylamide gel and detected by autoradiography. The samples were from reactions containing the following constructs: lane 1, pgHCV.1-195; lane 2, pgHCV.1-173; lane 3, pgHCV.1-153.

#### **Figure 2**

##### **Confocal images of the intracellular localisation of core proteins and lipid droplets.**

- 20 BHK C13 cells were harvested 20 hours after electroporation and fixed with 4% paraformaldehyde, 0.1% Triton X-100. Indirect immunofluorescence was performed with antibody JM122 and an anti-mouse secondary antibody conjugated with FITC. Lipid droplets were stained with oil red O. Panels A, D, G, J, M, P, S and V show the distributions of core protein. Panels B, E, H, K, N, Q, T and W show the locations of lipid droplets. Panels C, F, I, L, O, R, U and X are merged images of core protein and lipid droplets. Cells were electroporated with RNA from the following constructs:
- 25 panels A, B and C, pSFV.1-195; panels D, E and F, pSFV.1-173; panels G, H and I, pSFV.1-169; panels J, K and L, pSFV.1-153; panels M, N and O, pSFV. Δ155-161; panels P, Q and R, pSFV. Δ161-166; panels S, T and U, pSFVΔ125-144; panels V, W and X, pSFV.1-124, 145-152.
- 30

### Figure 3

**Effect of expression of core proteins on the ability to detect ADRP in BHKC13 cells by confocal microscopy.** Cells were harvested 20 hours after electroporation and fixed with methanol. ADRP was detected with anti-adipophilin antibody and core protein with 308 antisera. Secondary antibodies were an anti-mouse IgG conjugated with FITC (for anti-adipophilin) and anti-rabbit IgG conjugated with Cy5 (for 308 antisera). Panels A, D, G, J, M and P are images of ADRP localisation. Panels B, E, H, K, N, and Q are images of core distribution. Panels C, F, I, L, O and R show the merged images of core and ADRP distributions. Cells were electroporated with RNA from the following constructs: panels A, B and C, pSFV.1-195; panels D, E and F, pSFV.1-173; panels G, H and I, pSFV.1-169; panels J, K and L, pSFV.1-153; panels M, N and O, pSFV.Δ155-161; panels P, Q and R, pSFV.Δ161-166.

### Figure 4

**Effect of expression of core proteins on the ability to detect ADRP in MCA RH7777 cells by confocal microscopy.** Cells were examined as described in the legend for Figure 3.

### Figure 5

**Effect of expression of core protein on the abundance of ADRP.** BHK C13 cells were electroporated with RNA from pSFV.1-195 and pSFV.1-153 and extracts were prepared at the times indicated following electroporation. Aliquots of cell extracts were electrophoresed on 10% polyacrylamide gels and then the proteins were transferred to nitrocellulose membrane for Western blot analysis. The upper panels show membranes probed with JM122 antibody while, in the lower panels, membranes were probed with anti-adipophilin antibody. Bands corresponding to core proteins, expressed from pSFV.1-195 and pSFV.1-153, and ADRP are arrowed.

**Figure 6****Effect of lipid globule targeting sequences on stability and cleavage of core protein.**

A. Western Blot analysis of extracts prepared from cells which were harvested 16 hours after electroporation following treatment with proteasomal inhibitor MG132. Aliquots of extracts containing the same number of cell equivalents were analysed with antibody JM122. The samples were from cells electroporated with RNA from the following constructs: lanes 1 and 2, pSFV.1-195; lanes 3 and 4, pSFV.1-124, 145-152; lanes 5 and 6, pSFV.Δ125-144; lanes 7 and 8, pSFV.1-153; lanes 9 and 10, no RNA. Samples in lanes with odd numbers were prepared from cells not treated with MG132. Samples in lanes with even numbers were prepared from cells which had been incubated in the presence of MG132 (final concentration 2.5 μM) from 4 hours after electroporation.

B. Western blot analysis of extracts prepared from cells which were harvested 16 hours after electroporation. Aliquots of extracts containing the same number of cell equivalents were analysed with antibody JM122. The samples were from cells electroporated with RNA from the following constructs: lane 1, pSFV.1-195; lane 2, pSFV.1-124, 145-152; lane 3, pSFV.1-153; lane 4, pSFV.Δ125-144. The two forms of core protein produced by pSFV.Δ125-144 which have been either cleaved or not cleaved (C and UC respectively) at the internal processing site are arrowed.

**EXAMPLES****MATERIALS AND METHODS***Cell Lines*

Baby hamster kidney (BHK) C13 cells were maintained in Glasgow modified Eagle's medium supplemented with 10% newborn calf serum, 100 IU/ml penicillin/streptomycin and 5% tryptose phosphate broth. The rat hepatoma cell line, MCA RH7777, was maintained in minimal essential Eagle's medium supplemented with 20% foetal bovine serum, 100 IU/ml penicillin/streptomycin, 1 x non-essential amino acids and 2 mM

L-glutamine.

### *Immunological Reagents*

Antibody JM122 was a mouse monoclonal antibody raised against a purified fusion  
5 protein, expressed in bacteria, which was composed of the N-terminal 118 amino acid  
residues of core protein encoded by HCV strain Glasgow linked to a histidine tag.  
Antisera 308 was raised in rabbits against a branched peptide  
([A/P]KPQRKTKRNT[I/N]RRPQDVKFPGG)<sub>8</sub>K<sub>7</sub>A. The peptide consists of residues  
5-27 of core protein encoded by HCV strain Glasgow (SEQ ID. No. 1). The two  
10 degenerate sites at positions 1 and 12 were introduced to obtain antisera which would be  
reactive against core proteins from other isolates. The adipophilin antibody was obtained  
from Cymbus Biotechnology Ltd.

Secondary antibodies were obtained from Sigma with the exception of Cy5 conjugated  
15 goat anti-rabbit IgG which was obtained from Amersham.

### *Construction of Plasmids*

Plasmids containing the coding region for the core protein of HCV strain Glasgow were  
obtained by combining fragments from two constructs called core.pTZ18 and 5'-ΔNS2  
20 (provided by M. McElwee and R. Elliott). Core.pTZ18 possesses nucleotide residues  
337-915 of the HCV strain Glasgow genome and 5'-ΔNS2 contains residues 1-2895.  
DNA fragments from these plasmids were combined in a vector called pGEM1 to give a  
construct termed pgHCV.CE1E2. This plasmid contains nucleotide residues 337-2895 of  
the HCV strain Glasgow genome and therefore encodes the core, E1 and E2 proteins of  
25 this isolate.

For cloning purposes, the sequences immediately upstream of residue 337 were modified  
to contain the recognition sequences for Bgl II and Kpn I restriction enzyme sites and  
immediately downstream of residue 2895, an oligonucleotide was inserted which encodes  
30 a translational stop codon followed by the sequences for a Bgl II restriction enzyme site.  
To create pgHCV.CE1E2, a Bgl II DNA fragment containing the core, E1 and E2

sequences was inserted into the Bam HI site of pGEM1; this plasmid was further modified by introducing a Bgl II enzyme site at the Eco RI site in the pGEM backbone. Construction of a derivative plasmid, pgHCV.1-195 was achieved by inserting an oligonucleotide (GCTGAGATCTA) that had both a translational stop codon and the sequences for a Bgl II enzyme site between a Fsp I enzyme site at residue 925 in the HCV genome and a Hind III enzyme in the pGEM backbone. Thus, pgHCV.1-195 encodes the N-terminal 195 amino acids of HCV strain Glasgow. The nucleotide and predicted amino acid sequence of this region of HCV strain Glasgow is shown in SEQ ID. No. 1. From pgHCV.1-195, the following series of constructs were made which had various regions of the HCV coding region removed (in 1 to 3 and 6, the numbers following pgHCV represent the amino acid residues of HCV strain Glasgow encoded by each construct):

1. pgHCV.1-173 was constructed by inserting an oligonucleotide GTAACCTTCCTG GTTGCTCTTGAGATCTA between the Bst EII (at nucleotide residue 841 in the HCV strain Glasgow genome) and Hind III enzyme sites (located in the pGEM backbone) in pgHCV.1-195.
2. pgHCV.1-169 was constructed by inserting an oligonucleotide GTAACCTTTGAG ATCTA between the Bst EII (at nucleotide residue 841 in the HCV strain Glasgow genome) and Hind III enzyme sites (located in the pGEM backbone) in pgHCV.1-195.
3. pgHCV.1-153 was constructed by inserting an oligonucleotide CTGGCGCATTGA GATCTA between the Bst XI (at nucleotide residue 792 in the HCV strain Glasgow genome) and Hind III enzyme sites (located in the pGEM backbone) in pgHCV.1-195.
4. pgHCV.Δ155-161 was constructed by inserting an oligonucleotide CTGGCCCATG GTGTAACTATGCAACAG between the Bst XI and Bst EII enzyme sites (at nucleotide residues 792 and 841 respectively in the HCV strain Glasgow genome) in pgHCV.1-195. This construct lacks the nucleotide sequences encoding residues 155 to 161 of the core protein of HCV strain Glasgow.
5. pgHCV.Δ161-166 was constructed by inserting another oligonucleotide CTGGCCCATGGCGTCCGGGTTCTGGAAGACG between the Bst XI and Bst EII sites in pgHCV.1-195. This construct lacks the nucleotide sequences encoding residues 161

to 166 of the core protein of HCV strain Glasgow.

6. pgHCV.1-124, 145-152 was constructed by inserting an oligonucleotide CGATA GAGGCGCTGCCAGGGCCCTGGCGTGAGATCTA between the Cla I (at nucleotide residue 710 in the HCV strain Glasgow genome) and Hind III enzyme sites (located in the pGEM backbone) in pgHCV.1-195.

7. pgHCV.Δ125-144 was constructed by inserting a 400 bp Kpn I/Bst XI DNA fragment from pgHCV.1-124,145-152 (which contains residues 1-124 and 145-152) into a 2970 bp Kpn I/Bst XI DNA fragment from pgHCV.1-195 (which contains residues 153-195).

For expression in tissue culture cells, Bgl II DNA fragments carrying the relevant HCV sequences were prepared from the pgHCV plasmid series and inserted into the Bam HI site of a Semliki Forest virus vector pSFV1. The resultant plasmids were termed the pSFV. series (e.g. pSFV.1-195).

#### *In Vitro Translation*

Proteins were translated *in vitro* using a coupled transcription/translation kit supplied by Promega. Reactions used 1 µg of DNA as template and were carried out according to manufacturer's instructions.

#### *In Vitro Transcription*

Prior to electroporation, RNA was transcribed *in vitro* from the appropriate pSFV plasmid which had been linearised at a Spe I enzyme site. Typical reactions were carried out in a volume of 20 µl and contained 40 mM Tris (pH 7.5), 6 mM MgCl<sub>2</sub>, 2mM spermidine, 10 mM NaCl, 1 mM DTT, 1 mM ATP, 1 mM CTP, 1 mM UTP, 0.5 mM GTP, 1 mM m<sup>7</sup>G(5')ppp(5')G cap analogue, 50 units Rnasin, 50 units SP6 RNA polymerase and 2 µg linearised DNA. Reactions were performed at 37°C for 2 hours. Products of the reaction were analysed by agarose gel electrophoresis to examine the quality and quantity of RNA synthesised prior to use in electroporations.



### *Preparation of Cells Competent for Electroporation*

Cells were washed and treated with trypsin for detachment from tissue culture containers. Detached cells were suspended in 20 ml of growth medium and centrifuged at 100 g for 5 min at room temperature. Cell pellets were suspended in 50 ml of PBSA and centrifuged as previously. Pellets were suspended in PBSA at a final concentration of about  $2 \times 10^7$  cells/ml.

### *Electroporation of Cells and Preparation of Cell Extracts*

0.8 ml of competent cells were mixed with *in vitro* transcribed RNA in an electroporation cuvette (0.4 cm gap) and pulsed twice at either 1.2 kV, 25  $\mu$ F (for BHK C13 cells) or 0.36 kV, 960  $\mu$ F (for MCA RH7777 cells). Between pulses, the cell/RNA suspension was gently mixed. Following electroporation, cells were diluted in growth medium and seeded onto either tissue culture dishes or coverslips in 24-well tissue culture plates and then incubated at 37°C.

15

To prepare extracts, electroporated cells were harvested by removing the growth medium and washing the cell monolayers with PBS. Cells were scraped into PBS and pelleted by centrifugation at 100 g for 5 mins at 4°C. The cell pellet was solubilised in sample buffer consisting of 160 mM Tris (pH 6.7), 2% SDS, 700mM  $\beta$ -mercaptoethanol, 10% glycerol, 0.004% bromophenol blue.

20

Alternatively, sample buffer was added directly to cells which had been washed with PBS. Cells were solubilised at a concentration of approximately  $4 \times 10^6$  cell equivalents per ml sample buffer. Samples were heated to 100°C for 5 mins to fully denature proteins and nucleic acids.

25

### *SDS-PAGE and Western Blot Analysis*

Samples were prepared for electrophoresis and proteins were separated on polyacrylamide gels cross-linked with 2.5% (wt/wt) N,N'-methylene bisacrylamide using standard techniques. Polypeptides were detected either by autoradiography or by staining using Coomassie brilliant blue.

30

For Western blot analysis, proteins were separated on polyacrylamide gels and transferred to nitrocellulose membrane using standard techniques. The nitrocellulose membrane was blocked in 3% gelatin, 20 mM Tris (pH 7.5), 500 mM NaCl for at least 6 hours at 37°C prior to incubation with the primary antibody. Incubations with the primary antibody (diluted to 1/500 for adipophilin antibody and 1/1000 for JM122) were performed in 1% gelatin, 20 mM Tris (pH 7.5), 500 mM NaCl, 0.05% Tween 20 at either room temperature or 37°C for approximately 3-4 hours. Following extensive washing with 20 mM Tris (pH 7.5), 500 mM NaCl, 0.05% Tween 20, the membrane was incubated for 2 hours at room temperature with anti-mouse IgG conjugated with horse radish peroxidase in the same solution as for the primary antibody and at a dilution of 1/1000. Bound antibody was detected by enhanced chemiluminescence.

#### *Indirect Immunofluorescence and Staining of Lipids*

Cells on 13 mm coverslips were fixed in either methanol at -20°C or 4% paraformaldehyde, 0.1% Triton X-100 (prepared in PBS) at 4°C for 30 mins. Following washing with PBS and blocking with PBS/CS (PBS containing 1% newborn calf serum), cells were incubated with primary antibody (diluted in PBS/CS at 1/200 for JM122 antibody, 1/1000 for 308 antisera and 1/100 for adipophilin antibody) for 2 hours at room temperature. Cells were washed extensively with PBS/CS and then incubated with conjugated secondary antibody (either anti-mouse or anti-rabbit IgG raised in goat) for 2 hours at room temperature. Cells were washed extensively in solutions of PBS/CS followed by PBS and finally H<sub>2</sub>O before mounting on slides using Citifluor. Samples were analysed using a Leiss LSM confocal microscope.

Following incubation with both antibodies and washing, lipid droplets were stained in paraformaldehyde-fixed cells by briefly rinsing coverslips in 60% propan-2-ol followed by incubation with 0.5ml 60% propan-2-ol containing oil red O for 1.5-2 mins at room temperature. Coverslips were briefly rinsed with 60% propan-2-ol, washed with PBS and H<sub>2</sub>O and mounted as described above. The oil red O staining solution was prepared from a saturated stock of approximately 1% oil red O dissolved in propan-2-ol. Before staining, the stock was diluted with H<sub>2</sub>O and then filtered.

## RESULTS

### Example 1 Expression of HCV core protein and variants in tissue culture cells

5

Presently, there is no system available for propagating HCV in tissue culture cells. Therefore, expression of HCV gene products necessitates the use of heterologous expression systems. For short-term expression in mammalian cells, a variety of viral vectors have been utilised including vaccinia virus, Sendai virus and adenovirus. A further alternative is the Semliki Forest virus (SFV) system in which in vitro transcribed RNA, that encodes the SFV replication proteins as well as a heterologous protein but not the SFV structural proteins, is introduced into tissue culture cells. Introduction of nucleic acid into cells may be achieved by several routes but, in the examples given, the method of choice is electroporation.

15

BHK cells were electroporated with RNA from the series of pSFV constructs. 20 hours following electroporation, cells were harvested and extracts prepared. Samples were electrophoresed on a 10% polyacrylamide gel and, following electrophoresis, the proteins were transferred to nitrocellulose membrane for Western blot analysis.

20

Probing the membrane with the core-specific monoclonal antibody JM122 revealed a major single species in each sample which corresponds to core protein. The apparent molecular weights of the proteins made by pSFV.1-195 and two truncated variants, pSFV.1-173 and pSFV.1-169, are approximately 21 kDa and are almost identical (Figure 1A, lanes 1-3). Cleavage between the core and E1 coding regions occurs between residues 191 and 192. However, there is additional data which reveals that the core protein is further processed by cleavage around residue 174 (Moradpour *et al.*, 1996) this cleavage site will be referred to as the internal processing site. The precise residue at which this second cleavage event occurs is not known. Hence, in agreement with Figure 1A, lanes 1-3, it would be predicted that the three constructs named above would generate products of similar molecular weights.

30

Additional evidence for a cleavage event close to residues 169-173 occurring within tissue culture cells is shown in Figure 1B. Here, polypeptides translated *in vitro* from the pGEM versions of 3 core variants reveal that the unprocessed species made from pgHCV.1-195 is larger than that from pgHCV.1-173 (compare lanes 1 and 2). As would be predicted from the coding sequences for the third truncated form of core, the major species synthesised from pSFV.1-153 has a lower apparent molecular weight than that from pSFV.1-195 (Figure 1A, compare lanes 1 and 4). The major species made by the internal deletion mutants pSFV. $\Delta$ 155-161 and pSFV. $\Delta$ 161-166 are intermediate in size between those produced by pSFV.1-195 and pSFV.1-153 (Figure 1A, lanes 5 and 6). Again, this agrees well with predictions based on the number of amino acids removed in these variants (7 in pSFV. $\Delta$ 155-161 and 6 in pSFV. $\Delta$ 161-166). It is also evident that there is a significant amount of material produced by the two internal deletion variants which has a higher molecular weight than the fully processed form of core. This presumably represents reduced cleavage at the internal processing site which may result from the removal of certain residues in these mutants which are necessary for fully efficient processing. To conclude, the core proteins and its variants produced by the SFV constructs can be detected by a core-specific antibody and their apparent molecular weights are in agreement with predictions from the nucleotide sequences and previously published data.

### Example 2 - Intracellular distribution of HCV core protein

Previous studies have revealed that the HCV core protein can associate with lipid droplets within the cytoplasm of cells (Barba, G. *et al.*, 1997; Moradpour, D. *et al.*, 1996). This conclusion was arrived at by combining the techniques of immune electron microscopy with the ability to stain lipid with osmium tetroxide. However, this method suffers from the disadvantages that it is time-consuming and osmium tetroxide can stain other biological molecules (e.g proteins) in addition to lipid. Therefore, we developed a method for detecting proteins firstly by indirect immunofluorescence followed by staining of lipid droplets with the oil-soluble colourant oil red O. Combined with the

method of confocal microscopy, it is possible to visualise the intracellular localisations of core protein and lipid droplets separately and together. A typical example is shown in Figure 2, panels A-C. Here, BHK C13 cells have been electroporated with pSFV.1-195 RNA and, following incubation at 37°C for 20 hours, the cells have been examined by both indirect immunofluorescence and staining with oil red O. In panel A, the core protein produced by pSFV.1-195 is seen to locate to vesicular structures in the cytoplasm. Panel B reveals the distribution of lipid droplets in the same cell. By merging these data (panel C), it is evident that core protein is sited around the lipid droplets. These data therefore agree with previously published results for constructs expressing the full-length coding region of core.

**Example 3 - Association of HCV core protein with intracellular lipid droplets requires amino Acids 161 to 166 and 125 to 144**

Results with the constructs which produce truncated forms of core protein indicate that proteins consisting of 173 and 169 amino acids of the core coding region also locate to droplets (Figure 2, panels D-I). By contrast, expressing only the N-terminal 153 residues results in loss of localisation to droplets and a diffuse cytoplasmic distribution is observed (Figure 2, panels J-L). Thus, residues of core protein between amino acids 154 and 169 are required for localisation to droplets. Studies with the internal deletion mutants pSFV.Δ155-161 and pSFV.Δ161-166 further examined segments within this 16 amino acid region which may be important for core protein localisation. From the resultant data, removal of residues between 155 and 161 did not affect lipid droplet association whereas removal of residues between 161 and 166 gave a diffuse cytoplasmic pattern (Figure 2, compare panels M-O with P-R). Hence, between residues 154 and 169, amino acids from 161 to 166 play an essential role in the ability of core protein to locate to lipid droplets.

Further analysis of other internal deletion mutants (which removed residues 9-43, 4-75 and 80-118) showed that the core proteins made by these constructs continued to associate with lipid droplets (data not shown). Hence, these regions are dispensable for

binding to droplets. However, a construct expressing a core variant in which residues 125 to 144 had been deleted failed to distribute to droplets and gave a diffuse cytoplasmic fluorescence (Figure 2, panels S, T and U). This mutant therefore identifies a second region in addition to the segment between 161 and 166 which is necessary for association with droplets. The data suggest that both sets of sequences are required for targeting to lipid droplets. In agreement with these data, a core variant which is truncated at residue 152 and lacks amino acids 125 to 144 also fails to bind to droplets (Figure 2, panels V, W and X). Additionally, this protein, in which both sets of targeting sequences are deleted, is present in low amounts in electroporated cells as a consequence of degradation.

#### **Example 4 Effect of localisation of core protein on the lipid droplet associated protein ADRP**

At present, there are few proteins identified in mammalian cells which are known to associate with lipid droplets. One protein which has been recently identified is ADRP which is ubiquitously expressed in a number of tissue culture cell lines; ADRP mRNA has also been detected in a range of tissue types in mice. To examine whether the localisation of core to lipid droplets had any affect on ADRP, BHK C13 cells were electroporated with the series of pSFV constructs expressing core protein and its variants. An example of the data is shown in Figure 3. Panels A to C show images of three cells following electroporation with pSFV.1-195, only one of which contains core protein (Panel B). Immunofluorescent results with the adipophilin antibody (panel A) reveal that ADRP is located on vesicular structures, consistent with its previously assigned association with lipid droplets. The protein is readily detected in the cells which do not express core protein, however, it is considerably reduced in abundance in the core-expressing cell. Observations from this and a series of other experiments consistently revealed that cells expressing core protein from pSFV.1-195 either lacked or contained barely detectable amounts of ADRP. Nonetheless, some cells in which both core protein and ADRP were present also were found; in general, such cells gave reduced fluorescence for the core protein. Hence, it was concluded that the loss of

ADRP was related to the levels of expression of core in individual cells. Results with the variants of core which continue to locate to lipid droplets gave identical data (see panels D-I and M-O). Thus, the majority of cells expressing core protein from constructs pSFV.1-173, pSFV.1-169 and pSFV.Δ155-161 contained quantities of ADRP which were barely detectable. By contrast, ADRP continued to be readily found in cells producing core proteins from pSFV.1-153 and pSFV.Δ161-166, the variants which do not associate with lipid droplets (see panels J-L and P-R). Thus, association of core protein with lipid droplets correlates with a loss of ability to detect ADRP by immunofluorescence. Any cell type specificity for this affect was tested by performing identical experiments in the rat hepatoma cell line, MCA RH7777. In these cells, core protein and its variants gave identical results for their ability to associate with lipid droplets and this again correlated with the levels of ADRP detected in core-expressing cells (Figure 4). Thus the effect of core protein on ADRP is not cell-type specific.

#### **Example 5    The Ability of Core Protein to Associate with Lipid Droplets Induces a Loss of ADRP**

The immunofluorescence data revealed that the association of core protein and its variants with lipid droplets led to an inability to detect ADRP. It was possible that this was due to masking of ADRP by core. To examine directly the effect of core protein on the levels of ADRP, Western blot analysis was performed on cell extracts prepared at various times following electroporation with either pSFV.1-195 or pSFV.1-153 RNA. In parallel, immunofluorescence analysis was also performed on these cells and this revealed that expression of the core protein produced by the two RNAs was apparent in greater than 90% of cells. Analysis with antibody JM122 indicated that core protein could be detected from both constructs at 10 hours following electroporation and peaked by about 20 hours (Figure 5). The abundance of core protein produced by the two constructs was very similar by this time-point. From analysis of these samples with the ADRP-specific antibody, it is apparent that there is no change in the abundance of ADRP following electroporation with the pSFV.1-153 RNA. A third set of cells in this experiment which was electroporated with SFV RNA which expresses the HCV E1 and

E2 proteins also showed no reduction in ADRP levels with time. By contrast, there is a rapid reduction in ADRP levels to barely detectable quantities which mirrors the rise in core protein made from pSFV.1-195.

5 From staining of polyacrylamide gels with Coomassie brilliant blue, there were approximately equivalent amounts of protein in all samples. In addition, probing the membranes with another antibody for an endoplasmic reticulum-specific protein, calnexin, indicated that both pSFV.1-195 and pSFV.1-153 samples had similar quantities of this protein at the various times following electroporation. This effect of core expression on  
10 ADRP was consistently found in other experiments. Thus, the association of core protein with lipid droplets directly correlates with a specific reduction in the abundance of this protein in cells.

**Example 6 - Removal of lipid globule targeting sequences reduces protein stability  
15 and impairs cleavage at the internal processing site**

Immunofluorescence data with pSFV.1-124,145-152 and pSFV.Δ125-144 showed that the proteins made by these constructs gave diffuse fluorescence. In two separate experiments, Western blot analysis of extracts prepared from cells electroporated with  
20 RNA from these constructs revealed significantly reduced amounts of protein made by pSFV.1-124,145-152 as compared to that made by pSFV.1-195, pSFV.1-153 and pSFV.Δ125-144 (Figure 6A, compare lane 3 with lanes 1, 5 and 7 and Figure 6B, compare lane 2 with lanes 1, 3 and 4 ).

25 The level of reduction was approximately 5-fold. This low level of detectable protein was not the result of reduced amounts of RNA synthesised by *in vitro* reactions (data not shown). Addition of the proteasome inhibitor MG132 to a parallel culture of cells electroporated with pSFV.1-124, 145-152 gave rise to a significant (4-fold) increase in the amount of protein detected by Western blot analysis (Figure 6A, compare lane 4 with  
30 lane 3). Therefore, the reduction in protein levels from pSFV.1-124, 145-152 RNA is apparently not due to inefficient translation. These data suggest that removal of both



sets of sequences which are required for targeting to lipid droplets induces rapid degradation of the protein, analogous to that observed for ADRP in the presence of full-length core protein.

5 It was observed also that two protein products derived from pSFV. $\Delta$ 125-144 were detected by antibody JM122. From their mobilities, it was assumed that the upper band represented protein which had not been cleaved at the internal processing site (labelled UC in Figure 6B, lane 4) while the lower band was processed (labelled C in Figure 6B). Examination of the relative intensities of these species indicates that the uncleaved  
10 product is more abundant (approximately 4-5 fold) than the cleaved material. This provides evidence that the sequences between 125 and 144, which are required for lipid droplet association also influence the efficiency of cleavage at the internal processing site. Cleavage at this site is mediated by a cellular signalase which may be membrane bound. Hence, disruption of the targeting function of these residues is likely to inhibit  
15 cleavage at the internal processing site and, from evidence of the maturation of related pestiviruses and flaviviruses, such an effect will reduce virus maturation and growth.

#### **Example 7 - *In Vitro* Binding Assay to Test Effects of Candidate Substances**

##### **20 *Synthesis of lipid targeting sequences and ADRP using in vitro transcription/translation***

Constructs suitable for *in vitro* synthesis of mRNA are produced by placing nucleotide sequences encoding core protein (e.g. pgHCV.1-195) or any other protein with core lipid globule targeting sequences (e.g. pgHCV. $\Delta$ 43-119) and ADRP are placed under the  
25 control of a suitable bacterial or bacteriophage RNA polymerase promoter e.g. SP6 or T7. RNA transcripts are prepared from each of these constructs using standard methods and the yields of RNA determined.

To produce *in vitro* translated protein, the *in vitro* synthesised RNA is added to an  
30 extract capable of synthesising polypeptides e.g. a reticulocyte lysate prepared from

rabbits or an extract from wheat germ; proteins may be radiolabelled by including an isotopically labelled amino acid such as  $^{35}\text{S}$ -methionine.

### *Assessing binding of proteins to lipid*

5

Membranous material prepared from animal cells (e.g. microsomal membranes) or synthetically prepared mixtures of triacylglycerol or cholesterol and phospholipid are mixed with the translated proteins and incubated. Lipid fractions are then recovered by centrifugation. The incorporation of proteins into lipid fractions may be determined either directly by SDS-PAGE of radiolabelled proteins, or indirectly by using antibodies which are functional in Western blot and/or ELISA procedures.

10

Combinations of RNA from core protein and ADRP may be mixed in the same reaction in various proportions to test the relative affinity of each protein for lipid. An example of a combination would be 9 parts pgHCV.1-195 RNA to 1 part ADRP RNA.

15

Candidate substances at a range of concentrations, such as from 1  $\mu\text{M}$  to 100 mM, are added to reactions and the effect of these substances on protein binding to lipid analysed using the methods indicated above. A suitable candidate substance is typically a substance that enhances or does not significantly impair lipid association of ADRP but which reduces or abolishes binding of core to lipid.

20

### **Example 8 - *In Vivo* Binding Assay to Test Effects of Candidate Substances**

BHK C13 cells are electroporated with SFV encoding HCV core protein (for example SFV.1-195) as described above. At various time points after electroporation, candidate substances are added to cells at concentrations which are not cytotoxic (as determined with mock electroporated cells, for example). Following incubation at 37°C, cells are harvested and cell extracts prepared. Extracts are analysed by Western blot analysis (antibody JM122) to examine the abundance of core protein and determine the efficiency

30

of cleavage at the internal processing site. The relative abundance of core protein in treated as compared to untreated cells could also be quantitated by ELISA.

5 In addition, cells are fixed and examined by a combination of indirect immunofluorescence (for the core and ADRP proteins) and oil red O staining (for lipid droplets) as described above. This can be used to determine whether the intracellular distribution and abundance of core and ADRP has been altered by the presence of the candidate substances. Western blot analysis may also be used to confirm whether the candidate substance had any affect on ADRP levels.

10

A suitable candidate substance is typically a substance that prevents or reduces core association with droplets, causes reduced levels of core protein and/or impaired cleavage at the internal processing site. By contrast, the candidate substance should preferably not affect the intracellular distribution of ADRP and its abundance is typically either similar  
15 to or higher than in cells that do not express the core protein.

**Example 9 - Assessing anti-viral affects of candidate substances in transgenic animals expressing core or in chimpanzees**

20 In transgenic animals expressing liver-specific core protein or animals (chimpanzees) infected with HCV, test substances are added at concentrations which were not toxic to the host.

*Transgenic animals expressing core protein in a liver-specific manner*

25

Transgenic mice which give liver-specific expression of core protein are known in the art. Expression of core protein is associated with the development of steatosis and hepatocellular carcinoma in two lines of such animals (Moriya, K. *et al.*, 1998 and Moriya, K. *et al.*, 1997); both pathologies are associated with HCV infection. Similar transgenic  
30 mice may be produced with similar phenotypes and used to examine the effect of

substances which prevent core association with lipid droplets on these pathological changes.

5 The effect of candidate substances on core protein localisation and levels may be determined in transgenic animals using cells obtained by liver biopsies and tested using the techniques described in Example 8. Alternatively, or in addition, the effect of a candidate substance of the development of steatosis and hepatocellular carcinoma in these animals may be determined. The efficacy of candidate substances may be measured by a reduction in the pathological changes which occur e.g. reduced hepatosteatosis and  
10 significant delays or prevention of the onset of carcinoma.

*Chimpanzees infected with HCV*

The effect of a substance on HCV replication in infected chimpanzees is assessed by  
15 RT-PCR analysis of sera taken at regular intervals from the animal. Biopsy material from the liver may also be tested for the presence of negative-strand HCV RNA by RT-PCR using standard techniques (see Conry-Cantilena, 1997 for review and references contained therein). Efficacy of the candidate substance is assessed by the reduction in the levels of HCV RNA as measured in either or both assays. A reduction  
20 in viral titre by a factor of at least 2 to 3 logs is indicative of an anti-viral effect.

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope  
25 and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of  
30 the following claims.

## References

- Atschul *et al.*, 1990, J Mol Biol: 403-410.
- Altschul *et al.*, 1994, Nature Genetics 6:119-129.
- Barba, G. *et al.*, 1997. Proc. Natl. Acad. Sci. 94: 1200-1205
- Claverie & States (1993) Computers and Chemistry 17:191-201
- 5 Conry-Cantilena, 1997, Tibtech 15: 71-76
- Devereux *et al.*, 1984, Nucleic Acids Research 12: 387
- Engelman *et al.*, 1986, Ann Rev, Biophys. Chem 15: 343
- Heid *et al.*, 1998, Cell Tiss Res 294: 309-321
- Moradpour, D. *et al.*, 1996, Virology 222; 51-63
- Moriya, K. *et al.*, 1998, Nature Medicine 4; 1065-1067
- 10 Moriya, K. *et al.*, 1997, J. Gen. Virol. 78; 1527-1531
- Patton, S. and Huston, G.E., 1986, Lipids 21; 170-174
- Wootton & Federhen, 1993, Computers and Chemistry 17:149-163

## SEQUENCE LISTING

## SEQ ID No 1. - HCV Core Protein

GGTGCTTGCGAGTGCCCCGGGAGGTCTCGTAGACCGTGCACCATGAGCACGAATCCTAAA 360  
CCACGAACGCTCACGGGGCCCTCCAGAGCATCTGGCACGTGGTACTCGTGCTTAGGATTT  
M S T N P K 6

CCTCAAAGAAAAACCAAACGTAACACCAACCGTCGCCCACAGGACGTTAAGTTCCCGGGT 420  
GGAGTTTCTTTTTGGTTTGCATTGTGGTTGGCAGCGGGTGTCTTGCAATTCAAGGGCCCA  
P Q R K T K R N T N R R P Q D V K F P G 26

GGCGGTCAGATCGTTGGTGGAGTTTACTTGTTGCCGCGCAGGGGCCCTAGATTGGGTGTG 480  
CCGCCAGTCTAGCAACCACCTCAAATGAACAACGGCGCGTCCCCGGGATCTAACCCACAC  
G G Q I V G G V Y L L P R R G P R L G V 46

CGCGCGACGAGGAAGACTTCCGAGCGGTGCGAACCTCGAGGTAGACGTCAGCCTATCCCC 540  
GCGCGCTGCTCCTTCTGAAGGCTCGCCAGCGTTGGAGCTCCATCTGCAGTCGGATAGGGG  
R A T R K T S E R S Q P R G R R Q P I P 66

AAGGCACGTCGGCCCAAGGGCAGGAACCTGGGCTCAGCCCCGGGTATCCTTGGCCCCCTCTAT 600  
TTCCGTGCAGCCGGGTTCCTTACCCGAGTCGGGCCCATAGGAACCGGGGAGATA  
K A R R P K G R N W A Q P G Y P W P L Y 86

GGCAATGAGGGTTGCGGGTGGGCGGGATGGCTCCTGTCCCCCAGTGGCTCTCGGCCTAGT 660  
CCGTTACTCCCAACGCCACCCGCCCTACCGAGGACAGGGGGTCACCGAGAGCCGGATCA  
G N E G C G W A G W L L S P S G S R P S 106

TGGGGCCCCAACGACCCCCGACGTAGGTGCGGCAATTTGGGTAAGGTCATCGATACCCTT 720  
ACCCCGGGGTGCTGGGGGCTGCATCCAGCGCGTTAAACCCATTCCAGTAGCTATGGGAA  
W G P N D P R R R S R N L G K V I D T L 126

ACGTGCGGCTTCGTGATCTCATGGGGTACATACCGCTCGTCGGCGCCCCCTCTTAGAGGC 780  
TGCACGCCGAAGCAGCTAGAGTACCCCATGTATGGCGAGCAGCCGCGGGGAGAATCTCCG  
T C G F V D L M G Y I P L V G A P L R G 146

GCTGCCAGGGCCCTGGCGCATGGCGTCCGGGTTCTGGAAGACGGTGTGAACTATGCAACA 840  
CGACGGTCCCGGGACCGCGTACCGCAGGCCCAAGACCTTCTGCCACACTTGATACGTTGT  
A A R A L A H G V R V L E D G V N Y A T 166

GGTAACCTTCCTGGTTGCTCTTTCTCTATCTTCCTTCTGGCCCTGCTCTCTTGCTGACT 900  
CCATTGGAAGGACCAACGAGAAAGAGATAGAAGGAAGACCGGGACGAGAGAACGGACTGA  
G N L P G C S F S I F L L A L L S C L T 186

GTGCCCCGCTTCAGCCTACCAAGTGCGCAAC 930  
CACGGGCGAAGTCGGATGGTTACGCGTTG  
V P A S A Y Q V R N 196

## SEQ ID No 2. - HCV Core Protein - Amino acids 125 to 144

ACCCTTACGTGCGGCTTCGTCGATCTCATGGGGTACATACCGCTCGTCGGCGCCCCCTCTT 777  
 TGGGAATGCACGCCGAAGCAGCTAGAGTACCCCATGTATGGCGAGCAGCCGCGGGGAGAA  
 T L T C G F V D L M G Y I P L V G A P L 144

## SEQ ID No 3. - HCV Core Protein - Amino acids 161 to 166

GGTGTGAACTATGCAACA 840  
 CCACACTTGATACGTTGT  
 G V N Y A T 166

## SEQ ID No.4 - human ADRP - nucleotide sequence

CGTCTTCGGGACGCGCCCGCTCTTCGCCTTTTCGCTGCAGTCCGTCGATTTCTTTCTCCAG 60  
 GAAGAAAAATGGCATCCGTTGCAGTTGATCCACAACCGAGTGTGGTGA CT CGGGTGGTCA 120  
 ACCTGCCCTTGGTGAGCTCCACGTATGACCTCATGTCCTCAGCCTATCTCAGTACAAAGG 180  
 ACCAGTATCCCTACCTGAAGTCTGTGTGTGAGATGSCAGAGAACGGTGTGAAGACCATCA 240  
 CCTCCGTGGCCATGACCAGTGCTCTGCCCATCATCCAGAAGCTAGAGCCGCAAATTGCAG 300  
 TTGCCGATACCTATGCCTGTAAGGGGCTAGACAGGATTGAGGAGAGACTGCCTATTCTGA 360  
 ATCAGCCATCAACTCAGATTGTTGCCAATGCCAAAGGCGCTGTGACTGGGGCAAAAGATG 420  
 CTGTGACGACTACTGTGACTGGGGCCAAGGATTCTGTNGCCAGCACGATCACAGGGGTGA 480  
 TGGACAAGACCAAAGGGGCGAGTGACTGGCAGTGTGGAGAAGACCAAGTCTGTGGTCAGTG 540  
 GCAGCATTAACACAGTCTTGGGGAGTCGGATGATGCAGCTCGTGAGCAGTGGCGTAGAAA 600  
 ATGCACTCACCAAATCAGAGCTGTTGGTAGAACAGTACCTCCCTCTCACTGAGGAAGAAC 660  
 TAGAAAAAGAAGCAAAAAAAGTTGAAGGATTTGATCTGGTT CAGAAGCCAAGTTATTATG 720  
 TTAGACTGGGATCCCTGTCTACCAAGCTTCACTCCCGTGCCTACCAGCAGGCTCTCAGCA 780  
 GGGTTAAAGAAGCTAAGCAAAAAAGCCAACAGACCATTCTCAGCTCCATTCTACTGTTC 840  
 ACCTGATTGAATTTGCCAGGAAGAATGTGTATAGTGCCAATCAGAAAATT CAGGATGCTC 900  
 AGGATAAGCTCTACCTCTCATGGGTAGAGTGGAAAAGGAGCATTGGATATGATGATACTG 960  
 ATGAGTCCCACTGTGCTGAGCACATTGAGTCACGTACTCTTGCAATTGCCCGCAACCTGA 1020  
 CTCAGCAGCTCCAGACCACGTGCCACACCCTCCTGTCCAACATCCAAGGTGTACCACAGA 1080  
 ACATCCAAGATCAAGCCAAGCACATGGGGGTGATGGCAGGCGACATCTACTCAGTGTTC 1140  
 GCAATGCTGCCTCCTTTTAAAGAAGTGTCTGACAGCCTCCTCACTTCTAGCAAGGGGCAGC 1200  
 TGCAGAAAATGAAGGAATCTTTAGATGACGTGATGGATTATCTTGTTAACAACACGCCCC 1260  
 TCAACTGGCTGGTAGGTCCCTTTTATCCTCAGCTGACTGAGTCTCAGAATGCTCAGGACC 1320

AAGGTGCAGAGATGGACAAGAGCAGCCAGGAGACCCAGCGATCTGAGCATAAACTCATT	1380
AAACCTGCCCCCTATCACTAGTGCATGCTGTGGCCAGACAGATGACACCTTTTGTATGTT	1440
GAAATTAACCTTGCTAGGCAACCCTAAATTGGGAAGCAAGTAGCTAGTATAAAGGCCCTCA	1500
ATTGTAGTTGTTTCCAGCTGAATTAAGAGCTTTAAAGTTTCTGGCATTAGCAGATGATTT	1560
CTGTTACCTGGTAAGAAAAGAATGATAGGCTTGTGAGAGCCTATAGCCAGAACTCAGAA	1620
AAAATTCAAATGCACTTATGTTCTCATTCTATGGCCATTGTGTTGCCTCTGTTACTGTTT	1680
GTATTGAATAAAAACATCTTCATGTGGGCTGGGGTAGAAACTGGTGTCTGCTCTGGTGTG	1740
ATCTGAAAAGGCGTCTTCACTGCTTTATCTCATGATGCTTGCTTGTAAACTTGATTTTA	1800
GTTTTTCATTTCTCAAATAGGAATACTACCTTTGAATTCAATAAAATTCACTGCAGGATA	1860
GACCAGTTNAGNAGCAAACANNCANGTACACNNAAGANAC	1900

SEQ ID No. 5 - human ADRP - Amino acid sequence

MetAlaSerValAlaValAspProGlnProSerValValThrArgVal	16
ValAsnLeuProLeuValSerSerThrTyrAspLeuMetSerSerAla	32
TyrLeuSerThrLysAspGlnTyrProTyrLeuLysSerValCysGlu	48
MetXaaGluAsnGlyValLysThrIleThrSerValAlaMetThrSer	64
AlaLeuProIleIleGlnLysLeuGluProGlnIleAlaValAlaAsp	80
ThrTyrAlaCysLysGlyLeuAspArgIleGluGluArgLeuProIle	96
LeuAsnGlnProSerThrGlnIleValAlaAsnAlaLysGlyAlaVal	112
ThrGlyAlaLysAspAlaValThrThrThrValThrGlyAlaLysAsp	128
SerValAlaSerThrIleThrGlyValMetAspLysThrLysGlyAla	144
ValThrGlySerValGluLysThrLysSerValValSerGlySerIle	160
AsnThrValLeuGlySerArgMetMetGlnLeuValSerSerGlyVal	176
GluAsnAlaLeuThrLysSerGluLeuLeuValGluGlnTyrLeuPro	192
LeuThrGluGluGluLeuGluLysGluAlaLysLysValGluGlyPhe	208
AspLeuValGlnLysProSerTyrTyrValArgLeuGlySerLeuSer	224
ThrLysLeuHisSerArgAlaTyrGlnGlnAlaLeuSerArgValLys	240
GluAlaLysGlnLysSerGlnGlnThrIleSerGlnLeuHisSerThr	256
ValHisLeuIleGluPheAlaArgLysAsnValTyrSerAlaAsnGln	272
LysIleGlnAspAlaGlnAspLysLeuTyrLeuSerTrpValGluTrp	288
LysArgSerIleGlyTyrAspAspThrAspGluSerHisCysAlaGlu	304
HisIleGluSerArgThrLeuAlaIleAlaArgAsnLeuThrGlnGln	320



LeuGlnThrThrCysHisThrLeuLeuSerAsnIleGlnGlyValPro	336
GlnAsnIleGlnAspGlnAlaLysHisMetGlyValMetAlaGlyAsp	352
IleTyrSerValPheArgAsnAlaAlaSerPheLysGluValSerAsp	368
SerLeuLeuThrSerSerLysGlyGlnLeuGlnLysMetLysGluSer	384
LeuAspAspValMetAspTyrLeuValAsnAsnThrProLeuAsnTrp	400
LeuValGlyProPheTyrProGlnLeuThrGluSerGlnAsnAlaGln	416
AspGlnGlyAlaGluMetAspLysSerSerGlnGluThrGlnArgSer	432
GluHisLysThrHis	437

## CLAIMS

1. A method for identifying a substance capable of affecting a viral infection, which method comprises:

- (a) providing a lipid globule targeting sequence, as a first component;
- (b) providing a lipid globule, as a second component;
- (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and
- (d) determining whether the substance disrupts the interaction between the first and second components;

wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof.

2. A method according to claim 1 wherein the substance to be tested is administered to a cell, the lipid globule targeting sequence is expressed in said cell and the lipid globule is a natural constituent of said cell.

3. A method according to claim 1 or 2 further comprising:

- (e) administering a virus to a cell in the absence of a said substance which has been determined to disrupt the interaction between the first and second components;
- (f) administering the virus to the cell in the presence of the said substance; and
- (g) determining if the said substance reduces or abolishes the susceptibility of the cell to viral infection or the effects of viral infection.

4. A method according to any one of claims 1 to 3 wherein the lipid globule targeting sequence comprises amino acids from 125 to 144 and/or 161 to 166 of the HCV core protein.

5. A method for identifying a substance for treating or preventing a viral infection, which method comprises determining whether said substance can upregulate expression of adipocyte-specific differentiation related protein (ADRP) in a mammalian cell.
6. A method according to any one of claims 1 to 5 wherein the viral infection is a hepatitis infection or other viral infection of the human or animal liver.
7. A method according to any one of claims 2 to 6 wherein said cell is a liver cell.
8. A substance identified by the method of any one of the preceding claims.
9. A substance according to claim 7 wherein the substance has not previously been known to affect viral infection.
10. A substance capable of disrupting an interaction between (i) a lipid globule targeting sequence and (ii) a lipid globule for use in affecting a viral infection, wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof.
11. A protein comprising a lipid globule targeting sequence for use in preventing or treating a viral infection wherein the targeting sequence comprises an HCV core protein or a fragment, derivative, variant or homologue thereof
12. A protein according to claim 11 wherein the targeting sequence comprises amino acids from 125 to 144 and/or 161 to 166 of the HCV core protein.
13. A polynucleotide encoding a protein according to claim 11 or 12 sequence for use in affecting a viral infection.
14. Use of a protein according to claim 11 or 12, or a polynucleotide according to claim 13 in the manufacture of a medicament for use in affecting a viral infection

15. Use of a substance in the manufacture of a medicament for use in affecting a viral infection, wherein the substance has been identified by the method of any one of claims 1 to 7.

16. Use of a substance in the manufacture of a medicament for use in affecting a viral infection wherein said substance can upregulate expression of ADRP in a mammalian cell.

ABSTRACT



VIRAL THERAPEUTICS

An method for identifying a substance for affecting a viral infection is described. The method comprises:

- (a) providing a lipid globule targeting sequence, as a first component;
- (b) providing a lipid globule, as a second component;
- (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and
- (d) determining whether the substance disrupts the interaction between the first and second components;

wherein the targeting sequence comprises a hepatitis C virus (HCV) core protein or a fragment, derivative, variant or homologue thereof.


**THIS PAGE BLANK (USPTO)**



**Fig.1**


**THIS PAGE BLANK (USPTO)**






**Fig. 2 (1)**

**THIS PAGE BLANK (USP19)**




**Fig. 2 (2)**

**THIS PAGE BLANK (USPTO)**



**Fig. 2 (3)**


**THIS PAGE BLANK (USPTO)**



**Fig. 3 (1)**


**THIS PAGE BLANK (USPTO)**






**Fig. 3 (2)**

**THIS PAGE BLANK (15/11/16)**




**Fig. 4 (1)**

**THIS PAGE BLANK (USPTO)**



**Fig. 4 (2)**

**This Page Blank (uspto)**




**Fig. 5**


**THIS PAGE BLANK (USPTO)**



**A**



**B**



**Fig. 6**

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**